Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Gene Therapy Market
5.1. COVID-19 Landscape: Gene Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Gene Therapy Market, By Indication
8.1. Gene Therapy Market, by Indication, 2024-2033
8.1.1. Acute Lymphoblastic Leukemia (ALL)
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Inherited Retinal Disease
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Large B-cell Lymphoma
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. ADA-SCID
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Melanoma (lesions)
8.1.5.1. Market Revenue and Forecast (2021-2033)
8.1.6. Beta-Thalassemia Major/SCD
8.1.6.1. Market Revenue and Forecast (2021-2033)
8.1.7. Head & Neck Squamous Cell Carcinoma
8.1.7.1. Market Revenue and Forecast (2021-2033)
8.1.8. Peripheral arterial disease
8.1.8.1. Market Revenue and Forecast (2021-2033)
8.1.9. Spinal Muscular Atrophy (SMA)
8.1.9.1. Market Revenue and Forecast (2021-2033)
8.1.10. Others
8.1.10.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Gene Therapy Market, By Vector Type
9.1. Gene Therapy Market, by Vector Type, 2024-2033
9.1.1. Lentivirus
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. AAV
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. RetroVirus & gamma RetroVirus
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Modified Herpes Simplex Virus
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Adenovirus
9.1.5.1. Market Revenue and Forecast (2021-2033)
9.1.6. Non-viral Plasmid Vector
9.1.6.1. Market Revenue and Forecast (2021-2033)
9.1.7. Others
9.1.7.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Gene Therapy Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Indication (2021-2033)
10.1.2. Market Revenue and Forecast, by Vector Type (2021-2033)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Indication (2021-2033)
10.1.3.2. Market Revenue and Forecast, by Vector Type (2021-2033)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Indication (2021-2033)
10.1.4.2. Market Revenue and Forecast, by Vector Type (2021-2033)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Indication (2021-2033)
10.2.2. Market Revenue and Forecast, by Vector Type (2021-2033)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Indication (2021-2033)
10.2.3.2. Market Revenue and Forecast, by Vector Type (2021-2033)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Indication (2021-2033)
10.2.4.2. Market Revenue and Forecast, by Vector Type (2021-2033)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Indication (2021-2033)
10.2.5.2. Market Revenue and Forecast, by Vector Type (2021-2033)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Indication (2021-2033)
10.2.6.2. Market Revenue and Forecast, by Vector Type (2021-2033)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Indication (2021-2033)
10.3.2. Market Revenue and Forecast, by Vector Type (2021-2033)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Indication (2021-2033)
10.3.3.2. Market Revenue and Forecast, by Vector Type (2021-2033)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Indication (2021-2033)
10.3.4.2. Market Revenue and Forecast, by Vector Type (2021-2033)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Indication (2021-2033)
10.3.5.2. Market Revenue and Forecast, by Vector Type (2021-2033)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Indication (2021-2033)
10.3.6.2. Market Revenue and Forecast, by Vector Type (2021-2033)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Indication (2021-2033)
10.4.2. Market Revenue and Forecast, by Vector Type (2021-2033)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Indication (2021-2033)
10.4.3.2. Market Revenue and Forecast, by Vector Type (2021-2033)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Indication (2021-2033)
10.4.4.2. Market Revenue and Forecast, by Vector Type (2021-2033)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Indication (2021-2033)
10.4.5.2. Market Revenue and Forecast, by Vector Type (2021-2033)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Indication (2021-2033)
10.4.6.2. Market Revenue and Forecast, by Vector Type (2021-2033)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Indication (2021-2033)
10.5.2. Market Revenue and Forecast, by Vector Type (2021-2033)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Indication (2021-2033)
10.5.3.2. Market Revenue and Forecast, by Vector Type (2021-2033)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Indication (2021-2033)
10.5.4.2. Market Revenue and Forecast, by Vector Type (2021-2033)
Chapter 11. Company Profiles
11.1. REGENXBIO, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Oxford BioMedica plc
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Dimension Therapeutics, Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Bristol-Myers Squibb Company
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. SANOFI
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Applied Genetic Technologies Corp
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. F. Hoffmann-La Roche Ltd.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Bluebird Bio, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Novartis AG
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics)
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms